Ken Kengatharan, Phd Mba Email and Phone Number
Ken Kengatharan, Phd Mba work email
- Valid
- Valid
- Valid
Ken Kengatharan, Phd Mba personal email
- Valid
Ken Kengatharan, Phd Mba phone numbers
A biopharma executive with extensive experience in successfully setting up, securing capital, and growing multiple companies. My major focus is to enable the translation of multiple innovative ideas around biology, tech, and engineering into solution-based transformative healthcare for patients.Interests: Orphan drugs & rare diseases (use of Tx, TxDx, digital Tx, functional medicine, medical devices, gene Tx >2.0), healthcare delivery, distributed ledger tech/blockchain [v1 to v(n>1)], AI/ML, hIoT, innovative ways to prepare + fund (incl. PIPE) high growth companies in healthcare: private/public (incl. S1-IPO, RTO, DL) on NYSE/NASDAQ, HKEX, SGX, LSE, SIX.New pharma-biotech industry paradigm: Drug company --> Therapeutics management company (where a drug is part of a solution)New R&D paradigm: Common diseases ("blockbusters") -> “Orphanization” (via precision medicine) -> Orphan diseases ("nichebusters")Since 1998, experience: A. With a great team and supportive investors in each case, set up 7 companies (6 biotechs); now on 3+ cos + raised >$185MM in equity capital (mainly from blue-chip funds and biopharma).B. R&D: idea to Ph. 2/3: R&D & operations C. Corporate: BD&L (>$1Bn), corpdev, finance, pre-commercial D. Co-author of multiple articles and an invited presenter/panelist/moderator at biotech finance/R&D meetings incl. co-chairing international conferences on orphan drugs & rare diseases(I) Lecture series: “Freakonomics® of factors that determine the failure of a biotech company,” [Stanford (Aug, 2011), UCSF (Apr, 2012), London (Aug, 2012), Houston (Dec, 2013), Emory (Jan, 2019), SAGE (Nov, 2020)] (II) Delivered: Cardiology Grand Rounds Feb. 6, 2014: "Oral Anticoagulant Therapy in Patients with Prosthetic Heart Valve: Brief History, Challenges, and Future” (DeBakey Heart & Vascular Center, Houston Methodist, TX)(III) 2013 R&D Leadership Summit Interview discussing a new R&D investment risk-sharing model for pharma-biotech. [Conference Forum]Current: Board member at Auxesia Orion, Helios Orion, Renexxion, Apollorion Global, Radix Blend Co, and Advisor@Stanford’s SPARK programPast: BOD at Armetheon, EPi3, Athenagen, Altheos; Venture Advisor @Spire Bioventures; Visiting Scientist @Stanford, Advisory Board @Stanford's Cardinal Free Clinics, Mentor @UCSF (Entrepreneurship Prog.), Panelist@Stanford GSB's Ignite ProgramExperience: Start-up, translating ideas, investment+growth, Private Co to Public Co prep., M&A, licensing, business strategy, capital efficient R&D, product dev., IP, digital systems, executive coaching
Atheneos Ventures
View- Website:
- atheneoscapital.com
- Employees:
- 4
-
Managing General PartnerAtheneos VenturesSanta Clara, Ca, Us
-
Board Director And Cbo [Renexxion, Inc., Holdco Of Renexxion Ireland, Ltd.]Renexxion Ireland Ltd Apr 2024 - PresentRoscrea, Co. Tipperary, IeRenexxion, Inc. is a US-based biotechnology company with a wholly owned Irish subsidiary; Renexxion Ireland Limited. We are committed to delivering innovative drugs to patients with a high unmet need in gastrointestinal disorders with its pipeline in a pill: Naronapride. [see www.renexxion.com] -
Board Director And Cbo [Renexxion Ireland, Ltd.]Renexxion Ireland Ltd Aug 2021 - PresentRoscrea, Co. Tipperary, IeRenexxion Ireland Ltd. is a privately held biopharmaceutical company committed to delivering new drugs to patients with GI motility disorders with its R&D operations and drug development team based in Ireland. The company is developing naronapride, a potentially best-in-class, late-phase clinical-stage drug candidate that possesses a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both of which are clinically validated targets and work in both the upper and lower GI tract. Renexxion Ireland has a licensing and collaboration agreement with Dr Falk Pharma GmbH in greater Europe and Australasia. Naronapride is currently in a global Phase 2b (MOVE-IT) study in patients with gastroparesis (led by Dr Falk Pharma) and is ready for a Phase 2b study in patients with PPI-non-responsive symptomatic GERD in the US. For more information, refer to http://www.rnexltd.ie.
-
Member, Board Of Managers [Renexxion, Llc)Renexxion Ireland Ltd Sep 2014 - Mar 2024Roscrea, Co. Tipperary, Ie
-
Chairman, Board Of Managers [Renexxion, Llc]Renexxion Ireland Ltd Sep 2014 - Dec 2017Roscrea, Co. Tipperary, Ie
-
Managing General PartnerAtheneos Ventures Sep 2009 - PresentSanta Clara, California, UsAtheneos Ventures is a San Francisco Bay Area based healthcare focused evergreen fund dedicated to identifying and nurturing high quality, high risk (and potentially) game-changing healthcare companies previously focused on large indications and currently focusing on the orphan drugs and rare diseases space. [www.atheneosventures.com]
-
Board MemberApollorion Global Dec 2018 - PresentApollorion global is a corporate strategy advisory firm that partners with innovative healthcare companies to foster their growth. We deploy an experienced team that will work with the founders and senior leadership to execute on their vision. Where necessary, working with affiliates, we provide a comprehensive one-stop solution. Activities include strategic access to capital, enabling partnerships, developing commercial relationships. The company's registered office is in Dublin, Ireland. In the future, the company plans to have a presence in London, Singapore, Hong Kong, Sydney, and Seoul. -
DirectorRadix Blend Company Aug 2021 - PresentRadix Blend is a tech-enabled functional nutrition company developing an innovative way to create and deliver precision and personalized nutrition tied to feedback on health performance such as systemic glucose bioavailability. [Stage: Deep Stealth Mode]
-
Executive ChairmanHelios Orion Sep 2018 - PresentSanta Clara, California, UsHelios Orion, Corp. is an execution-focused corporate strategy advisory firm that partners with innovative healthcare and cleantech companies in key global markets to assist in their growth. The company's network has deep domain-specific expertise in all areas of corporate development and product development from discovery/prototype to commercialization in the global healthcare and cleantech industries. The company's experienced plug and play team works with founders and leadership team to execute on their vision including preparing to be a public company. Where necessary, working with affiliates, the company provides a comprehensive one-stop solution. Helios Orion's key focus areas include drug, diagnostics, medical devices, digital therapeutics, AI, and therapeutic foods as well as cross-border ecosystem collaboration and development in these innovation areas. Helios Orion was founded on 9/19/2018. The company is based in Santa Clara (California). In the future, the company plans to have a presence in Amsterdam, London, New York, Singapore, Hong Kong, Sydney, Dubai, and Seoul. -
ChairmanAuxesia Orion Jan 2023 - PresentSanta Clara, California, UsThe goal of Auxesia Orion, Inc. is to focus on tech-enabled patient-centric therapeutics management and commercialization for orphan diseases where drugs are only part of a solution. The company is involved in research and development, approval and technology-enabled commercialization of novel drugs for orphan diseases as well as patient centric-management of new therapeutic modalities. Auxesia Orion, Inc. was formally set-up on 8/8/2018. [Stage: Deep Stealth Mode] -
Chief Executive OfficerAuxesia Orion Aug 2018 - Dec 2023Santa Clara, California, UsThe goal of Auxesia Orion, Inc. is to focus on tech-enabled patient-centric therapeutics management and commercialization for orphan diseases where drugs are only part of a solution.
-
Principal PathfinderAnanke Pathfinder Jan 2022 - PresentStrategic Business AdvisorExecutive CoachCorporate Development Advisor
-
Venture AdvisorSpire Bioventures Apr 2015 - Dec 2017SPIRE Bioventures is a group of senior executives whose aim is to guide European Medical devices and biotech Start-ups gain visibility in the Bay Area ecosystem. The SPIRE Bioventures partners are dedicated equity partners who work together closely in a closed Network, serving customers as international consultants, advisors and board members. Website: http://spire-bioventures.com/
-
Member, Board Of DirectorsArmetheon, Inc. Oct 2011 - Aug 2017Santa Clara, California, UsArmetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company. In Q3, 2017, Armetheon merged with Espero Pharmaceuticals, Inc to become Espero BioPharma, Inc, a commercial-stage cardiovascular focused company with 3 marketed products and a potential blockbuster pipeline. [www.esperobio.com] -
President & IceoArmetheon, Inc. Dec 2016 - Jul 2017Santa Clara, California, UsArmetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active anticoagulant (tecarfarin) for all patients who need an oral anticoagulant including a targeted patient population with major unmet need. Unlike non-monitored oral anti-coagulant (NOAC) drugs that are direct inhibitors of thrombin or Factor Xa, tecarfarin could be used in patients with (i) prosthetic heart valves, and/or (ii) who have renal dysfunction (with one Phase III completed). The second drug candidate under development is budiodarone which is an oral Phase 2 clinical-stage drug candidate that is being investigated for its potential to suppress ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs) and for the treatment of patients with refractory atrial fibrillation. In early 2017, Armetheon merged with Espero Pharmaceuticals, Inc to become Espero BioPharma, Inc, a commercial-stage cardiovascular focused company with 3 marketed products and a potential blockbuster pipeline. [www.esperobio.com]
-
PresidentArmetheon, Inc. Sep 2012 - Nov 2016Santa Clara, California, UsArmetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active mid- late- stage drug candidates for defined high unmet need patient population. See above/website for additional info [www.armetheon.com]
-
President & Coo And IceoArmetheon, Inc. Sep 2012 - Feb 2015Santa Clara, California, UsArmetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active mid- late- stage drug candidates for defined high unmet need patient population. See above/website for additional info [www.armetheon.com]
-
President & Chief Scientific OfficerAltheos, Inc. Apr 2009 - Aug 2012Altheos is a biopharmaceutical company focused on the development of a new generation of promising, novel, small-molecule drugs for the treatment of ocular diseases in particular glaucoma. As President & CSO, I was responsible for all non-clinical and CMC activities related to the development of a new generation of topical eye drop therapy for glaucoma (including Scientific Strategy, non-clinical R&D and Strategy, R&D Operations and CMC). The lead compound, ATS907 for glaucoma/OHT entered Phase 2 clinical development in early 2012 and the back-up compound ATS8535 was ready for development. -
Member, Board Of DirectorsAltheos, Inc. Apr 2009 - Apr 2010Altheos is a biopharmaceutical company focused on development of a new generation of promising, novel, small-molecule drugs for the treatment of ocular diseases in particular glaucoma. See above.
-
Vice President, Translational Research And Scientific AffairsComentis, Inc. Jan 2008 - Mar 2009South San Francisco, Ca, UsCoMentis, Inc. is focused on the research and development of small molecule drugs to treat Alzheimer's disease and is at present mainly pursuing the development of beta-secretase inhibitor drugs in partnership with Astellas Pharma, Inc., under terms of an exclusive worldwide collaboration agreement initiated in 2008. As head of Pre-Clinical R&D (South San Francisco site), I was responsible for the angiogenesis program and the alpha-7 nicotinic receptor agonists (for use in neurological and inflammatory diseases) program and non-clinical R&D operations in South San Francisco. -
Vice President, Pre-Clinical R&DComentis, Inc. Oct 2005 - Dec 2007South San Francisco, Ca, UsAthenagen was founded based on technologies discovered at Stanford University to discover and develop drugs in the area of cholinergic angiogenesis. The company later acquired Osprey pharmaceutical which was developing novel alpha-7 nicotinic receptor agonists for cognitive dysfunction in various neurological disorders. As head of non-clinical R&D (including R&D operations and CMC), I was responsible for the angiogenesis program which was focused on developing new therapies for diabetic foot ulcer, neovascular age-related macular degeneration and diabetic macular edema.
-
Member, Board Of DirectorsComentis, Inc. Sep 2004 - Sep 2006South San Francisco, Ca, UsAthenagen was founded based on technologies discovered at Stanford University to discover and develop drugs in the area of cholinergic angiogenesis. The company later acquired Osprey pharmaceutical which was developing novel alpha-7 nicotinic receptor agonists for cognitive dysfunction in various neurological disorders. As head of non-clinical R&D (including R&D operations and CMC), I was responsible for the angiogenesis program which was focused on developing new therapies for diabetic foot ulcer, neovascular age-related macular degeneration and diabetic macular edema.
-
Staff Scientist (Cardiovascular Medicine)Stanford University School Of Medicine Jan 2004 - Sep 2005Palo Alto, Ca, UsCharacterization of a novel angiogenesis pathway discovered at Stanford and identifying new therapeutic uses for agents that modulated this pathway. This angiogenic pathway is termed "Cholinergic Angiogenesis." This scientific work was the basis of founding Athenagen, Inc. in 2004 that was later re-named CoMentis, Inc in 2007 when the company became a neurovascular biotech company. -
Vice President, Pre-Clinical R&DOxon Medica, Inc. Aug 2001 - Dec 2003OxoN Medica was developing novel nitric oxide donors that were also superoxide dismutase (SOD) mimetics. As head of non-clinical R&D, I was responsible for development of NCEs for angina, vascular complications in diabetes and neuroprotection in glaucoma.
-
Managing Director (Ceo), Cto And Board MemberEpi3 Aug 1998 - Jul 2001Founded by scientists, clinicians and IT experts, ePi3 was one of the early pioneers tasked with creating a comprehensive digital system for efficiently carrying out scientific research and drug development. ePi3 engaged Unisys Corporation (UK), an American global IT company, which made multi-million dollar commitment, and provided a team of 35 people (engineers, product architects, BD) to develop an integrated internet based digital system designed by us. This was one of the earliest systems that combined an early web-based database architecture with contextual, language independent and Bayesian inference-based search functionality (using the Autonomy(R) search engine) as a module to assist in linking scientific data and research papers with lab products to purchase (including reagents, chemicals etc.) and the ability for advertisers to buy specific non-trademarked keywords using small payments. This system was called, SCIFEX.In 1997, I invented and subsequently filed a patent for a new method for a global payment system using the internet which involved micro-payments, allowing people to purchase small items such as the ability to buy to read articles and books online on a page-by-page basis, and for people in different parts of the world to collaborate to purchase small items or services, as well as donate to charitiesUK Patent Application: Kengatharan, Muralitharan. A payment system for purchasing over the global computer network. GB0023672.9, published in September 2000. Prior experience in mathematical modeling, COBOL programming and data processing, were enormously helpful during this period.
-
Associate Research ScientistRhone-Poulenc Rorer (Now Sanofi) Aug 1992 - Aug 1993As a member of the discovery team within Cardiovascular group, I was given the responsibility to set up a secondary screening laboratory to help identify novel endothelin receptor antagonists. Endothelin, a potent vasoconstrictor peptide, was discovered a couple of years earlier.
Ken Kengatharan, Phd Mba Skills
Ken Kengatharan, Phd Mba Education Details
-
University Of LondonCardiovascular Pharmacology -
Durham UniversitySpecializing In Biotech Finance And Entrepreneurship
-
University Of LondonPharmacology
-
University Of LeedsPharmacology
Frequently Asked Questions about Ken Kengatharan, Phd Mba
What company does Ken Kengatharan, Phd Mba work for?
Ken Kengatharan, Phd Mba works for Atheneos Ventures
What is Ken Kengatharan, Phd Mba's role at the current company?
Ken Kengatharan, Phd Mba's current role is Managing General Partner.
What is Ken Kengatharan, Phd Mba's email address?
Ken Kengatharan, Phd Mba's email address is kk****@****ion.com
What is Ken Kengatharan, Phd Mba's direct phone number?
Ken Kengatharan, Phd Mba's direct phone number is +141544*****
What schools did Ken Kengatharan, Phd Mba attend?
Ken Kengatharan, Phd Mba attended University Of London, Durham University, University Of London, University Of Leeds.
What skills is Ken Kengatharan, Phd Mba known for?
Ken Kengatharan, Phd Mba has skills like Drug Development, Biotechnology, Clinical Development, Clinical Trials, Pharmacology, Life Sciences, Pharmaceutical Industry, Biopharmaceuticals, Start Ups, Drug Discovery, Strategy, R&d.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial